Press Releases

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Platform

BIND Therapeutics 03.15.2016

BIND Therapeutics and Synergy Pharmaceuticals Announce Collaboration to Develop ACCURINS® with Proprietary Uroguanylin Analogs for Targeting Gastrointestinal Receptors on Tumors

BIND Therapeutics 02.16.2016

AZD2811 ACCURINS® Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies

BIND Therapeutics 02.10.2016

BIND Therapeutics Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

BIND Therapeutics 01.27.2016

BIND Therapeutics Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) at the 2016 Genitourinary Cancers Symposium

BIND Therapeutics 01.07.2016

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer

BIND Therapeutics 12.16.2015

BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

BIND Therapeutics 12.14.2015

BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos

BIND Therapeutics 10.14.2015

bBIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

BIND Therapeutics 09.24.2015

BIND Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update

BIND Therapeutics 08.06.2015

Loading